# Syndax Pharmaceuticals Inc. (SNDX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $14.29, market value $1.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Syndax Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 4.4×**. Each dollar of revenue is priced at 4.4×.
- **Price / book: 19.3×**. The shares trade at 19.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Operating margin: -61.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -165.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -441.6%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -51.6%**. Return on all capital, debt included, is -51.6%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -39.5%**. Each dollar of assets produces -39.5% of profit.

## Growth
- **Revenue growth (1 yr): 627.8%** (5-yr 157.7%/yr). Revenue grew 627.8% over the last year, against 157.7% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 11.6%**. Earnings per share rose 11.6%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 5.32**. Debt is 5.32 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: net cash**. Syndax Pharmaceuticals Inc. holds more cash than debt.
- **Current ratio: 4.40** (quick 4.40). Current assets cover the next year's liabilities 4.40 times.
- **Altman Z-score: 1.37**. A Z-score of 1.37 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Syndax Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (11 analysts). 11 analysts cover Syndax Pharmaceuticals Inc.; the consensus is strong_buy, with an average price target of $37.27 (+161% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -4.4%** (YTD -37.6%, 3-mo -31.9%). The shares are down 4.4% over twelve months including dividends.
- **From 52-week high: -44.2%** (11.7% above the low). Trading 44% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 32**. An RSI of 32 is neutral.
- **Beta (1 yr): 0.74** (volatility 52%). Beta of 0.74 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SNDX · Page: https://foliofundamentals.com/stocks/sndx

Not investment advice.